This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Assess Platelet Dysfunction With Verify Now Assay

This study has been completed.
Information provided by (Responsible Party):
Nina D'Abreo, MD, Winthrop University Hospital Identifier:
First received: July 19, 2010
Last updated: August 8, 2012
Last verified: August 2012
The purpose of this study is to conduct a Verify now assay to detect platelet aggregation defects in patients with Myelodysplastic syndrome(MDS), immune thrombocytopenia purpura (ITP) and myeloproliferative disorders (MPD).

Platelet Aggregation Defects

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: "In-vitro Characterization of Platelet Dysfunction in Common Hematological Disorders Using the Verify Now Assay"

Resource links provided by NLM:

Further study details as provided by Nina D'Abreo, MD, Winthrop University Hospital:

Primary Outcome Measures:
  • platelet aggregation defects [ Time Frame: one year ]
    to assess platelet aggregation defects

Enrollment: 79
Study Start Date: December 2009
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
verify now assay
subjects who have Myelodysplastic syndrome, immune thrombocytopenia, and myeloproliferative disorders with platelet disorders

Detailed Description:
Verify Now is a rapid, simple, point-of service assay to measure platelet aggregation. The verify now assay is designed to assess platelet function based on the ability of activated platelets to bind fibrinogen. It is hoped that this study will detect the subtle platelet functional abnormalities in patients with hematological disorders.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
patients with platelet defects

Inclusion Criteria

- Patients with common blood disorders such as immune thrombocytopenia purpura(ITP) myelodysplastic syndrome MDS)and myeloproliferative disorders (MPV)

Exclusion Criteria

- Patients with normal platelet counts

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01167218

United States, New York
Winthrop University Hospital Oncology/Hematology Division
Mineola, New York, United States, 11501
Sponsors and Collaborators
Nina D'Abreo, MD
Principal Investigator: Nina D'abreo, MD Winthrop University Hospital
  More Information

Responsible Party: Nina D'Abreo, MD, Principal Investigator, Winthrop University Hospital Identifier: NCT01167218     History of Changes
Other Study ID Numbers: 09318
Study First Received: July 19, 2010
Last Updated: August 8, 2012

Keywords provided by Nina D'Abreo, MD, Winthrop University Hospital:
verify now assay for hematological disorders

Additional relevant MeSH terms:
Hematologic Diseases processed this record on June 23, 2017